Study Aiming to Measure the Impact on Immune Activation and Inflammatory Markers of Switching From a Triple Combination Antiretroviral Therapy (cART) to a Long Acting Dual Therapy in HIV-infected Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- HIV-1-infection
- Sponsor
- Centre Hospitalier de Cannes Simone Veil
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Evolution the trajectory of immune activation and inflammatory markers
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The purpose of the study is to measure the impact on immune activation and inflammatory markers of switching from a triple combination antiretroviral therapy (cART) to a long acting dual therapy in HIV-infected patients
Detailed Description
Patients meeting the inclusion criteria will be offered to participate to the study. In case of acceptance by given their writting consent, 6 ml of blood will be collected for measuring immune activation and inflammatory markers, during the blood test scheduled for the routine follow-up. Six months after cART change, an equal volume of blood will be collected for measuring the same immune activation and inflammatory markers
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients agreeing to participate to the study and to collect their data
- •HIV-1 infected subjects
- •Patients switching from a stable (at least 6 months) and successful triple cART to a long acting dual cART
- •Patients older than 18 yrs and regularly followed in Cannes and Nice hospitals
- •Patients with a healthcare card
Exclusion Criteria
- •HIV-2 infected subjects
- •Patients not being on successful and stable cART
- •Patients having being treated during acute HIV-infection
- •Patients modifying cART for virological failure
- •Subjects modifying their treatment for another combination than from a triple cART to a dual cART
- •Patients modifying cART during the 6 months of follow-up
- •Patients refusing to participate to the study
- •Patients included in an interventional study during the 6 months of follwo-up
- •Patient under juridical procedure
Outcomes
Primary Outcomes
Evolution the trajectory of immune activation and inflammatory markers
Time Frame: Baseline and 6 months after modiyfying cART
Assess the trajectory of immune activation and inflammatory markers change at 6 month after modifying cART
Secondary Outcomes
- Prevalence of patients with successful cART(1 month, 3 month, 6 month)